Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, October 28 at 2:00 PM ET

Register Free →

Search

Top

Back to Contracts

Clinical Trial Management and Coordination

Active

Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

This subcontract for Clinical Trial Management and Coordination supports the Department of Defense and the Department of the Army USAMRAA by providing day-to-day management of clinical trials for prime contractors on DHA research projects. The scope of work includes the development and execution of Study Management Plans, the coordination of multi-institutional data transfers, and the management of imaging products and specimen sharing. The contractor is responsible for ensuring all activities adhere to Good Clinical Practice standards and 45 CFR 46.102 using clinical coordinating center infrastructure. Key deliverables for this engagement include the finalized Study Management Plan and comprehensive data transfer logs. The project falls under NAICS code 541714 and was posted on May 21, 2026.

General Info

Subcontract for DoD clinical trial management, coordination, and data transfer under GCP standards.

Agency

Department Of Defense → Department Of The Army -- Usamraa

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Place of Performance

Not specified

Set-Aside

NONE

Documents

This scope was carved out of HT942526ORPCRA.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

DoW Orthopaedic, Clinical Research Award

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Timeline

PostedMay 21

subcontract

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more

AgencyDepartment Of Defense → Department Of The Army -- Usamraa

ContactsNo contacts available

OfficeN/A

Organization / AgencyDepartment Of Defense → Department Of The Army -- Usamraa

Office AddressN/A

ContactsNo contact information available

Full Description

Show more

Performs day-to-day management of clinical trials for prime contractors on DHA/DoD research projects. Develops and executes Study Management Plans, coordinates multi-institutional data transfer, and manages specimen and imaging product sharing. Ensures compliance with 45 CFR 46.102 and Good Clinical Practice (GCP) standards using clinical coordinating center infrastructure. Delivers the Study Management Plan and data transfer logs.

Similar Contracts

Same NAICS industry code

In Vivo Biodistribution Studies and Bioluminescence ImagingThis subcontract, titled In Vivo Biodistribution Studies and Bioluminescence Imaging, supports biotechnology projects for the Department of Veterans Affairs at the Harry S Truman Memorial Veterans Hospital. The selected provider will conduct animal studies to evaluate AAV vector specificity and off-target transduction. Key technical responsibilities include administering vectors to animal models, utilizing bioluminescence imaging via IVIS to track localization, and performing tissue harvesting for qPCR analysis to generate comprehensive biodistribution data reports. The work will be performed in Columbia, Missouri, and requires strict adherence to AAALAC and FELASA health standards. This opportunity is categorized under NAICS code 541714 and is managed by Rpo East. Interested parties should note the response deadline of November 4, 2026.

Rpo East (36C24E)

POSTED

DEADLINE

AAV Vector Binding and Internalization Testing (Kidney Tissue)This subcontract, issued by the Department of Veterans Affairs Rpo East for biotechnology projects at the Harry S Truman Memorial Veterans Hospital, involves specialized laboratory testing to verify the binding and internalization of AAV vectors. The selected provider will be responsible for preparing kidney tissue slices, incubating them with modified AAV vectors, and utilizing qPCR platforms, Agilent Fragment Analyzers, and fluorescence microscopy to analyze efficiency. All work must be performed in BSL-2 facilities, and the contractor is required to hold BSL-2 certification. The primary deliverable for this engagement is the provision of detailed validation reports focusing on internalization rates and binding affinity. The project is categorized under NAICS code 541714 and is based in Columbia, Missouri. Interested parties must respond by November 4, 2026.

Rpo East (36C24E)

POSTED

DEADLINE

Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)

Solicitation # W911SR-26-R-HEAL

The Capability Program Executive for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND) is establishing the Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) ecosystem. This continuous, open announcement seeks to build a network of pre-qualified partners to accelerate the development, testing, and fielding of next-generation medical defense solutions. The program focuses on two primary pillars: host-targeted resilience, which targets critical host systems like neurological and respiratory pathways to enhance physiological protection, and threat-targeted neutralization, which focuses on broad-spectrum countermeasures for prophylaxis and acute treatment. Priority is given to candidates designed for austere environments, featuring environmental stability without cold-chain reliance and simplified administration routes such as oral or intranasal delivery. The government is inviting two types of participants: MCM Development Collaborators, ranging from Phase I products through FDA licensure, and MCM Development Support Collaborators, such as CROs and CDMOs specializing in preclinical testing, cGMP manufacturing, and regulatory submissions. Interested parties must submit a white paper of no more than five pages detailing their product descriptions, efficacy data, regulatory status, and manufacturing capabilities. Acceptance into the PBA enables the subsequent award of project orders under the authority of 10 U.S.C sections 4021, 4022, and 4023. These agreements are not subject to the Competition in Contracting Act of 1984. All prospective awardees must be registered in the System for Award Management (SAM) database to receive payment.

POSTED

DEADLINE

AJ12--Development/Production - Kidney GEC-Specific AAV Vector

Solicitation # 36C24E27Q0009

The Department of Veterans Affairs is issuing a Sources Sought notice to identify capable vendors for the development and production of a kidney glomerular endothelial cell specific adeno-associated virus AAV vector. This project, funded by a VA ORD Merit award, aims to create a homing peptide enabled vector platform to target the glomerular endothelium to treat kidney injury and disease while reducing off target transduction. The scope of work is divided into three primary tasks: the engineering and incorporation of targeting peptides into the AAV capsid, testing vector binding and internalization in kidney tissue slices, and evaluating the specificity and efficiency of the modified vector through bioluminescence imaging and in vivo biodistribution studies. Qualified contractors must possess extensive onsite resources, including BSL 2 laboratories, specialized DNA and RNA facilities, and advanced instrumentation such as the Agilent Fragment Analyzer and various qPCR platforms. Vendors must demonstrate proven success in animal and human cell vector delivery and maintain full compliance with AAALAC and FELASA health standards. The government requires quarterly reporting, weekly videoconferences, and biannual face to face meetings. All generated data will be subject to Government Purpose Rights, and contractors must adhere to strict federal records management and information security protocols. Interested parties must submit a capability statement, relevant literature, and socio economic status details under NAICS 541714 by November 4, 2026.

Rpo East (36C24E)

POSTED

DEADLINE

MPS Platform Development & EngineeringThis subcontract focuses on the development and engineering of Microphysiological Systems and Organ-on-a-Chip platforms to support prime contractors on NIH/NIAID infectious disease projects. The scope of work involves engineering microfluidic devices, optimizing tissue-chip interfaces, and utilizing biocompatible polymers and precision pumps to integrate human variability into hardware and biological interfaces. The ultimate goal is to deliver a validated and reproducible platform that aligns with NIH and FDA guidance regarding New Approach Methodologies. Managed under the National Institutes of Health within the Department of Health and Human Services, the project falls under NAICS code 541714. The solicitation was posted on October 20, 2026, with a response deadline set for January 29, 2027.

National Institutes Of Health

POSTED

DEADLINE

Discovery Gateway to Reproductive Health InnovationThe National Institutes of Health, through the Eunice Kennedy Shriver National Institute of Child Health and Human Development, intends to establish the Discovery Gateway to Reproductive Health Innovation. This initiative aims to create a comprehensive, open-access web-based visualization platform and knowledgebase to advance research on male and female reproductive health issues, including infertility, uterine fibroids, endometriosis, preeclampsia, and preterm birth. By integrating multi-omic, pharmacogenomic, and clinical data, the Gateway seeks to fill critical knowledge gaps and provide the biomedical community with shared infrastructure to identify biomarkers, drug targets, and disease mechanisms. The primary objective of this project is to catalyze the discovery of new treatments and cures while fostering public-private partnerships and the development of commercial products. This effort aligns with recommendations from the Task Force on Research Specific to Pregnant Women and Lactating Women. The opportunity is currently listed as a forecast, with administrative oversight provided by the Obstetric and Pediatric Pharmacology and Therapeutics Branch.

National Institutes Of Health

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases (NIAID) has issued solicitation RFA-AI-28-012 to establish a consortium of Translational Centers Using Microphysiological Systems for Infectious Diseases (TCMID). The primary objective is to refine and validate human tissue models using Microphysiological Systems (MPS) to a level consistent with regulatory qualifications, thereby promoting their adoption by product developers and reducing reliance on laboratory animals. This initiative aligns with NIH and FDA guidance on New Approach Methodologies (NAMs) to accelerate the development of safer medical interventions by capturing human variability and patient-specific characteristics. The program is structured around an Administrative Core, a Qualification Core, and Scientific Cores, with a heavy emphasis on technical readiness, reproducibility, and regulatory acceptance. Key deliverables include the validation of assays for specific endpoints and the submission of regulatory packages. Applicants must be domestic entities, as foreign organizations and foreign subawards are strictly prohibited. Required personnel must possess deep expertise in infectious diseases, MPS platforms, bioinformatics, and FDA submission processes. Applications are due by January 29, 2027, and must be submitted via the NIH ASSIST system or approved institutional system-to-system solutions. Evaluation is based on an overall impact score considering the project's significance, the suitability of the investigators, and the quality of the institutional environment. Mandatory application components include a Data Management and Sharing Plan and a Benchmarks and Timeline PDF not exceeding six pages. Awardees must also adhere to strict cybersecurity incident reporting guidelines, notifying HHS within 48 hours of any discovery.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institutes of Health, under the Department of Health and Human Services, is seeking applications through solicitation RFA-AI-28-005 to continue the Immune Tolerance Network (ITN). This cooperative agreement aims to develop tolerogenic therapies for immune-mediated disorders, specifically focusing on autoimmune diseases, allergic diseases and asthma, and the immune-mediated consequences of transplantation. The network operates through four integrated functional areas: Leadership, Clinical Operations, Core Laboratory, and Bioinformatics. Its primary objectives include designing and conducting clinical trials, performing integrated mechanistic studies, and sharing research results. Eligible applicants include small businesses and other for-profit organizations, though non-domestic entities are ineligible. Applications are evaluated based on scientific and technical merit, with a primary focus on significance and the likelihood of exerting a sustained influence on the research field. Key requirements include maintaining active registrations in SAM.gov, eRA Commons, and Grants.gov, as well as adhering to strict cybersecurity incident reporting and human subject protection protocols. The project requires a minimum effort of 3.6 person months per year for the PD/PI and mandates participation in a kick-off meeting in Bethesda, Maryland, and bi-annual steering meetings. Applications must follow specific page limits for the research strategy subsections and include detailed plans for clinical trial implementation, data management, and biorepository services.

National Institutes Of Health

POSTED

DEADLINE

Immune Tolerance Network (UM1 Clinical Trial Required)

Solicitation # RFA-AI-28-005

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, is seeking applications under solicitation RFA-AI-28-005 to continue the Immune Tolerance Network. The primary goal of this initiative is the development of tolerogenic therapies targeting autoimmune diseases, allergic diseases and asthma, and immune-mediated consequences of transplantation. The network is tasked with the core functions of designing and conducting clinical trials, performing integrated mechanistic studies, and sharing the resulting data. This federal solicitation was posted on October 20, 2026, and requires responses by January 30, 2027. As a UM1 clinical trial requirement, the project emphasizes a collaborative approach to advancing medical treatments for immune-mediated disorders through rigorous clinical research and analysis.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed)

Solicitation # RFA-AI-28-012

The National Institute of Allergy and Infectious Diseases, under the National Institutes of Health, is soliciting proposals for the Translational Centers Using Microphysiological Systems for Infectious Diseases under solicitation number RFA-AI-28-012. This initiative aims to establish a consortium of centers focused on refining and validating human tissue models to study infectious diseases and test medical interventions. By leveraging New Approach Methodologies, the program seeks to create in vitro systems that capture human variability and patient-specific characteristics, ultimately accelerating the development of safer treatments while reducing costs and the reliance on laboratory animals. The primary objective is to advance these microphysiological systems to a level of regulatory qualification that encourages adoption by product developers and ensures regulatory acceptance. Interested parties must submit their responses by the deadline of January 30, 2027. This federal opportunity specifically focuses on bridging the gap between current research and regulatory use for infectious disease models, though it is noted that clinical trials are not allowed under this specific funding mechanism.

National Institute Of Allergy And Infectious Diseases

POSTED

DEADLINE

Barley Net Blotch Initiative (BNBI) Program 2 – Host and pathogen genetics

Solicitation # PROC-9177507

The Grains Research and Development Corporation is seeking a partner to deliver Program 2 of the Barley Net Blotch Initiative, a five-year national effort to combat the significant economic threat of net blotch in Australian barley. This specific program focuses on host and pathogen genetics to fast-track the development of durable host resistance. Key objectives include providing breeder-deployable validated markers, characterizing resistance sources, conducting pathogenic genomics research, establishing a durability risk-assessment framework, and assessing the feasibility of genome-editing. This solicitation, identified as PROC-9177507, was posted on October 19, 2026, with a response deadline of March 4, 2027. The project is part of a broader strategy involving pathogen surveillance and integrated disease management to reduce the estimated 122 million dollar annual loss caused by yield decreases and grain quality downgrades. Performance of the contract will span multiple major Australian cities, including Canberra, Sydney, Melbourne, Adelaide, Perth, Brisbane, Darwin, and Hobart.

Grains Research and Development Corporation

POSTED

DEADLINE

Pre-Clinical Models of Infectious Diseases

Solicitation # 75N93027R00003

The National Institute of Allergy and Infectious Diseases (NIAID) is issuing a ramp-on solicitation to award multiple IDIQ base contracts for the Preclinical Models of Infectious Diseases program. This initiative aims to expand the existing pool of contractors capable of developing and refining animal and animal replacement models to evaluate medical countermeasures, such as vaccines, therapeutics, and diagnostics. The program bridges the gap between in vitro testing and clinical evaluation, supporting regulatory submissions and the advancement of countermeasures against priority biodefense and emerging infectious agents. Successful offerors will be eligible to compete for task orders across four specific areas: Small Animal Models, Non-Human Primate Models, Animal Replacement and Non-traditional Animal Models, and the Generation and Distribution of Specialized Reagents. The scope of work emphasizes a wide array of pathogens, including pandemic-potential RNA viruses, antimicrobial-resistant infections, fungal diseases, and neglected tropical diseases. Proposals must be submitted electronically via the NIAID eCPS website, and applicants are required to have a valid NIH eRA Commons account for authentication and secure transmission.

National Institutes Of Health Niaid

POSTED

DEADLINE

in about 2 months

More opportunities from Department Of Defense → Department Of The Army -- Usamraa

Same awarding agency

Data Management and Research Sharing Plan DevelopmentThe contract seeks the design and implementation of a secure, compliant data management plan tailored for biomedical research, with a strong emphasis on preserving data integrity, adhering to FAIR principles—findable, accessible, interoperable, and reusable—and meeting federal requirements for data sharing. The plan must ensure that all research data is handled in a manner that supports long-term preservation, ethical use, and regulatory compliance, particularly under Department of Defense standards. The subcontractor will be responsible for developing structured policies and technical workflows that align with evolving federal mandates, enabling seamless data sharing while maintaining rigorous security protocols to protect sensitive biomedical information. The initiative is managed by the Department of the Army through USAMRAA under the broader Department of Defense, with the NAICS code 518210 indicating its focus on data processing and hosting services. The opportunity is open as a subcontract, with responses due by November 4, 2026. While the physical place of performance and point of contact are not specified, the work must be executed to meet federal compliance timelines and deliverables without reliance on proprietary or non-standard frameworks. The goal is to establish a scalable, audit-ready data infrastructure that supports ongoing and future biomedical research initiatives under federal oversight.

Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services

POSTED

DEADLINE

VCA Preservation & Perfusion Modality DevelopmentThis subcontract, titled VCA Preservation and Perfusion Modality Development, supports Defense Health Agency research projects through the Department of the Army USAMRRA. The primary objective is to develop and test strategies for preserving vascularized composite allografts, specifically focusing on implementing active perfusion modalities and static preservation to reduce ischemia-reperfusion injury. The technical execution of the contract requires the use of specialized equipment, including temperature-controlled chambers and perfusion pumps. The successful party is responsible for delivering comprehensive technical reports that detail the efficacy of these methods and provide optimized perfusion protocols.

Measuring, Dispensing, and Other Pumping Equipment Manufacturing

POSTED

DEADLINE

Clinical Graft Monitoring Tool PrototypingThis subcontract opportunity with the Department of the Army USAMRRA involves the development of assays, devices, and technology for clinical graft monitoring in support of Defense Health Agency research projects. The selected provider will prototype monitoring devices and integrate biomarkers into tools specifically designed for the human use factors associated with vascularized composite allotransplantation recipients. The project requires the delivery of a functional prototype or a validated assay kit. To qualify, providers must possess bio-engineering facilities and adhere to ISO 13485 or FDA Quality System Regulation standards. The work falls under NAICS code 541715 and is focused on advancing clinical monitoring capabilities for the Department of Defense.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

VCA Graft Rejection & Immunosuppression Biomarker AnalysisThis subcontract, titled VCA Graft Rejection and Immunosuppression Biomarker Analysis, is issued by the Department of the Army USAMRRA under the Department of Defense. The project focuses on the identification and validation of prognostic or diagnostic biomarkers for prime contractors supporting Defense Health Agency research. The primary scope of work involves analyzing human clinical samples to monitor immunosuppression levels and VCA graft rejection through the use of high-sensitivity assay equipment. To ensure compliance with human subject research standards, the contractor must maintain CLIA certification and obtain IRB approval. The expected deliverables include technical reports, assay results, and validated biomarker profiles. The contract is categorized under NAICS code 621511 and was posted on May 29, 2026.

Medical Laboratories

POSTED

DEADLINE

VCA Clinical Outcome Assessment ToolsThis subcontract, titled VCA Clinical Outcome Assessment Tools, is issued by the Department of the Army USAMRRA under the Department of Defense. The primary objective is to develop tools and metrics to measure the success and functional outcomes of VCA procedures for prime contractors working on Defense Health Agency research projects. This involves the design of both quantitative and qualitative tools specifically focused on quality of life assessments and return-to-duty metrics. The project requires strict adherence to 32 CFR 219.104 regulations regarding human subject research. The final deliverable for this effort is a validated scoring system or outcome measurement tool. The contract is categorized under NAICS code 541712 and was posted on May 29, 2026.

Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)

POSTED

DEADLINE

DoW Reconstructive Transplant, Concept Award

Solicitation # HT942526RTRPCA

The Defense Health Agency Contracting Activity is soliciting applications for the fiscal year 2026 Reconstructive Transplant Research Program Concept Award under solicitation HT942526RTRPCA. This program supports the exploration of highly innovative new concepts or untested theories that address critical problems in reconstructive transplantation, specifically those aligned with FY26 RTRP Focus Areas. The award is designed for high-risk, high-reward research that introduces new paradigms or creative perspectives, and it explicitly excludes clinical trials and incremental advances based on existing data. Early-career investigators at or above the postdoctoral fellow level are encouraged to apply. Funding is capped at 200,000 dollars per award for a maximum period of performance of 18 months, with an overall program appropriation of 12 million dollars. The selection process involves a two-tier review consisting of a peer review for technical merit followed by a programmatic review for relevance to military health and program priorities. Applicants must maintain active registrations in SAM.gov, eBRAP.org, and Grants.gov. Key submission requirements include a three-page Statement of Work, a one-page Innovation Statement, and a one-page Post-Award Transition Plan. All applications must be submitted by the specified deadlines, with full applications from extramural organizations required to go through the Grants.gov Workspace. Special attention is required for the disclosure of foreign affiliations of key personnel and the approval of the DHA R&D Office of Research and Regulatory Compliance for any research involving human or animal subjects.

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

DEADLINE

Statistical Analysis and Study DesignThis subcontract opportunity with the Department of the Army USAMRAA involves providing specialized biostatistical expertise to support prime contractors on DHA and DoD research projects. The selected provider will be responsible for developing statistical frameworks for hypotheses, determining sample sizes, and conducting power calculations for behavioral health or biomedical outcomes. Technical proficiency in SAS, R, or SPSS is required to deliver the Statistical Analysis Plan and the Final Data Analysis Report. Qualified candidates must hold an advanced degree in Statistics or Biostatistics to meet the professional requirements of the role. The project falls under NAICS code 541690 and is focused on high-level study design and statistical analysis to ensure the integrity of research outcomes for the Department of Defense.

Other Scientific and Technical Consulting Services

POSTED

DEADLINE

Clinical Ethics and Patient AdvocacyThis subcontract, titled Clinical Ethics and Patient Advocacy, supports prime contractors on DHA and DoD research projects by providing essential ethical guidance and patient advocacy. The scope of work includes reviewing study protocols for ethical compliance and developing strategic advice for patient recruitment and retention. Key deliverables consist of Ethics Review Reports and Patient Advocacy Guidance. The position requires specialized qualifications, specifically Clinical Ethicist certification or recognized Patient Advocacy credentials. This effort is managed under the Department of the Army USAMRAA within the Department of Defense, falling under NAICS code 541690.

Other Scientific and Technical Consulting Services

POSTED

DEADLINE

Intervention Material SupplyThis subcontract, titled Intervention Material Supply, involves the provision of drugs, medical devices, and surgical tools to prime contractors supporting DHA and DoD research projects. The selected provider is responsible for manufacturing and delivering interventions that demonstrate proven safety, stability, and dosing consistency. To ensure quality and compliance, the contractor must utilize GMP-certified facilities and maintain ISO 13485 certification for all medical devices. Deliverables include the physical intervention materials accompanied by formal Certificates of Analysis. This opportunity is associated with the Department of the Army USAMRRA under NAICS code 325412.

Pharmaceutical Preparation Manufacturing

POSTED

DEADLINE

Regulatory Compliance and Application SupportThe Regulatory Compliance and Application Support subcontract, issued by the Department of the Army under the Department of Defense, focuses on the preparation and submission of regulatory applications for prime contractors involved in DHA and DoD research projects. The scope of work includes managing FDA sponsor applications, ensuring strict adherence to 45 CFR 46.102, and creating clinical monitoring plans designed to mitigate operational risks. To qualify, personnel must possess a Regulatory Affairs Certification or demonstrate equivalent expertise in FDA guidelines. The primary deliverables for this engagement are comprehensive regulatory submission packages and detailed Clinical Monitoring Plans. This effort falls under NAICS code 541690 and is managed through the USAMRAA office.

Other Scientific and Technical Consulting Services

POSTED

DEADLINE

Clinical Support Tool & Knowledge Product DevelopmentThis subcontract for Clinical Support Tool and Knowledge Product Development supports prime contractors on Defense Health Agency projects through the creation of clinical practice guidelines, provider training materials, and patient-facing tools. The scope of work includes developing patient brochures, scientific journal publications, and medical simulations, all of which must adhere to strict medical publication standards and clinical guideline protocols. The project requires the use of specialized medical writing software and instructional design tools to deliver finalized published guidelines and software applications. This effort is managed under the Department of the Army within the Department of Defense, falling under NAICS code 541511.

Custom Computer Programming Services

POSTED

DEADLINE

Pre-clinical Animal Model TestingThis subcontract for Pre-clinical Animal Model Testing supports the Department of the Army and the Defense Health Agency by conducting animal studies to determine relevance to human orthopaedic biology. The scope of work includes managing specific animal species and strains, performing surgical or therapeutic procedures, and implementing necessary study controls. The selected provider must possess veterinary surgical facilities and animal housing, as well as maintain required IACUC approval and certification. The primary deliverables for this engagement are animal study data and biological impact reports. This effort falls under NAICS code 541720 and is designed to assist prime contractors in validating medical research through rigorous pre-clinical testing.

Research and Development in the Social Sciences and Humanities

POSTED

DEADLINE

Ready to Pursue This Opportunity?

Get AI-powered intelligence on this solicitation and the ones like it

Every page of the solicitation package shredded into a compliance breakdown

AI-powered matching based on your capabilities and past performance

Competitor and incumbent history on the requirement

Automated alerts on amendments, Q&A deadlines, and award

Join 750+ contractors already using CLEATUS